PE-conjugated Anti-NKG2D antibody(DMC287); IgG1 Chimeric mAb

Cat. No. DMC100287P

DIMA BIOTECH

PRODUCT INFORMATION

Clone ID	DMC287
Target	NKG2D
Synonyms	NKG2D;CD314;KLRK1;NK cell receptor D
Host Species	Rabbit
Description	PE-conjugated Anti-NKG2D antibody(DMC287); IgG1 Chimeric mAb
Delivery	Under Development
Uniprot ID	P26718
IgG type	Rabbit/Human Fc chimeric IgG1
Clonality	Monoclonal
Reactivity	Human
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1:100
Purification	Purified from cell culture supernatant by affinity chromatography
Formulation & Reconstitution	Liquid□PBS with 0.05% Proclin300, 1% BSA
Storage & Shipping	Store at 2°C-8°C for 6 months
Background	Natural killer (NK) cells are lymphocytes that can mediate lysis of certain tumor cells and virus-infected cells without previous activation. They can also regulate specific humoral and cell-mediated immunity. NK cells preferentially express several calcium-dependent (C-type) lectins; which have been implicated in the regulation of NK cell function. The NKG2 gene family is located within the NK complex; a region that contains several C-type lectin genes preferentially expressed in NK cells. This gene encodes a member of the NKG2 family. The encoded transmembrane protein is characterized by a type II membrane orientation (has an extracellular C terminus) and the presence of a C-type lectin domain. It binds to a diverse family of ligands that include MHC class I chain-related A and B proteins and UL-16 binding proteins; where ligand-receptor interactions can result in the activation of NK and T cells. The surface expression of these ligands is important for the recognition of stressed cells by the immune system; and thus this protein and its ligands are therapeutic targets for the treatment of immune diseases and cancers. Read-through transcription exists between this gene and the upstream KLRC4 (killer cell lectin-like receptor subfamily C; member 4) family member in the same cluster.
Usage	Research use only
Conjugate	PE-conjugated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

DIMA CONFIDENTIAL

Address: Wuhan institute of Biotechnology B7, Biolake No.666 Gaoxin Road, Wuhan, Hubei, China
Telephone: +1 2409940618(USA)
/+86-18062749453(China)
/+86-400-006-0995(China)
Email: info@dimabio.com
Website: www.dimabio.com

DIMABIO CONFIDENTIAL

Address: Wuhan institute of Biotechnology B7, Biolake No.666 Gaoxin Road, Wuhan, Hubei, China
Telephone: +1 2409940618(USA)
/+86-18062749453(China)
/+86-400-006-0995(China)

Email: info@dimabio.com
Website: www.dimabio.com